Acquired platelet disorders

Thrombosis Research

Volumn 141, Issue , 2016, Pages S73-S75

  Casari, Caterina ^a   Bergmeier, Wolfgang ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

acquired; disease; dysfunction; hemostasis; platelets; signaling

Indexed keywords

THROMBOCYTE ANTIBODY;

ARTICLE; DISEASE ASSOCIATION; HUMAN; KIDNEY FAILURE; LIVER DISEASE; MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; SYSTEMIC DISEASE; THROMBOCYTE DISORDER; THROMBOCYTE FUNCTION; UREMIA; VON WILLEBRAND DISEASE; ANIMAL; BLOOD; BLOOD PLATELET DISORDERS; COMPLICATION; HEMOSTASIS; METABOLISM; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; THROMBOCYTE;

ANIMALS; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; HEMOSTASIS; HUMANS; LIVER DISEASES; MYELOPROLIFERATIVE DISORDERS; UREMIA; VON WILLEBRAND DISEASES;

EID: 84989821324     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(16)30371-1     Document Type: Article

References (53)

1. 1 Metharom, P, Berndt, MC, Baker, RI, Andrews, RK, Current state and novel approaches of antiplatelet therapy. Arteriosclerosis, Thrombosis, and Vascular Biology 35 (2015), 1327–1338 doi:10.1161/ATVBAHA.114.303413.
2. 2 Konkle, BA, Acquired disorders of platelet function. Hematology Am Soc Hematol Educ Program 2011 (2011), 391–396 doi:10.1182/asheducation-2011.1.391.
3. 3 Scharf, RE, Drugs that affect platelet function. Semin Thromb Hemost 38 (2012), 865–883 doi:10.1055/s-0032-1328881.
4. 4 Shen, Y-MP, Frenkel, EP, Acquired platelet dysfunction. Hematol Oncol Clin North Am 21 (2007), 647–661 –vi. doi:10.1016/j.hoc.2007.06.001.
5. 5 Hassan, AA, Kroll, MH, Acquired disorders of platelet function. Hematology Am Soc Hematol Educ Program, 2005, 403–408 doi:10.1182/asheducation-2005.1.403.
6. 6 Di Minno, G, Cerbone, A, Usberti, M, Cianciaruso, B, Cortese, A, Farace, MJ, et al. Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. J Lab Clin Med 108 (1986), 246–252.
7. 7 Mannucci, PM, Tripodi, A, Hemostatic defects in liver and renal dysfunction. Hematology Am Soc Hematol Educ Program 2012 (2012), 168–173 doi:10.1182/asheducation-2012.1.168.
8. 8 Boccardo, P, Remuzzi, G, Galbusera, M, Platelet dysfunction in renal failure. Semin Thromb Hemost 30 (2004), 579–589 doi:10.1055/s-2004-835678.
9. 9 Lutz, J, Menke, J, Sollinger, D, Schinzel, H, Thürmel, K, Haemostasis in chronic kidney disease. Nephrol Dial Transplant 29 (2014), 29–40 doi:10.1093/ndt/gft209.
10. 10 Remuzzi, G, Benigni, A, Dodesini, P, Schieppati, A, Livio, M, De Gaetano, G, et al. Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. Journal of Clinical Investigation 71 (1983), 762–768.
11. 11 Eknoyan, G, Brown, CH, Biochemical abnormalities of platelets in renal failure. Evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase. Am J Nephrol 1 (1981), 17–23.
12. 12 Remuzzi, G, Perico, N, Zoja, C, Corna, D, Macconi, D, Viganò, G, Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. Journal of Clinical Investigation 86 (1990), 1768–1771 doi:10.1172/JCI114904.
13. 13 Vlachoyannis, J, Schoeppe, W, Adenylate cyclase activity and cAMP content of human platelets in uraemia. Eur J Clin Invest 12 (1982), 379–381.
14. 14 Rabiner, SF, Hrodek, O, Platelet factor 3 in normal subjects and patients with renal failure. Journal of Clinical Investigation 47 (1968), 901–912 doi:10.1172/JCI105782.
15. 15 Moal, V, Brunet, P, Dou, L, Morange, S, Sampol, J, Berland, Y, Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Nephrol Dial Transplant 18 (2003), 1834–1841.
16. 16 Marks, PW, Hematologic manifestations of liver disease. Semin Hematol 50 (2013), 216–221 doi:10.1053/j.seminhematol.2013.06.003.
17. 17 Violi, F, Basili, S, Raparelli, V, Chowdary, P, Gatt, A, Burroughs, AK, Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?. J Hepatol 55 (2011), 1415–1427 doi:10.1016/j.jhep.2011.06.008.
18. 18 Cines, DB, Cuker, A, Semple, JW, Pathogenesis of immune thrombocytopenia. Presse Med 43 (2014), e49–e59 doi:10.1016/j.lpm.2014.01.010.
19. 19 George, JN, el-Harake, MA, Raskob, GE, Chronic idiopathic thrombocytopenic purpura. N Engl J Med 331 (1994), 1207–1211 doi:10.1056/NEJM199411033311807.
20. 20 Takahashi, H, MOROI, M, Antibody against platelet membrane glycoprotein VI in a patient with systemic lupus erythematosus. Am J Hematol 67 (2001), 262–267 doi:10.1002/ajh.1128.
21. 21 Nurden, P, Tandon, N, Takizawa, H, Couzi, L, Morel, D, Fiore, M, et al. An acquired inhibitor to the GPVI platelet collagen receptor in a patient with lupus nephritis. J Thromb Haemost 7 (2009), 1541–1549 doi:10.1111/j.1538-7836.2009.03537.x.
22. 22 Heyns, AD, Fraser, J, Retief, FP, Platelet aggregation in chronic idiopathic thrombocytopenic purpura. J Clin Pathol 31 (1978), 1239–1243.
23. 23 Boylan, B, Chen, H, Rathore, V, Paddock, C, Salacz, M, Friedman, KD, et al. Anti-GPVI-associated ITP: An acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcR{gamma}-chain complex from the human platelet surface. Blood, 2004.
24. 24 Nieswandt, B, Schulte, V, Bergmeier, W, Mokhtari-Nejad, R, Rackebrandt, K, CAZENAVE, JP, et al. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med 193 (2001), 459–469.
25. 25 Palatinus, A, Adams, M, Thrombosis in systemic lupus erythematosus. Semin Thromb Hemost 35 (2009), 621–629 doi:10.1055/s-0029-1242716.
26. 26 Fayyaz, A, Igoe, A, Kurien, BT, Danda, D, James, JA, Stafford, HA, et al. Haematological manifestations of lupus. Lupus Sci Med, 2, 2015, e000078 doi:10.1136/lupus-2014-000078.
27. 27 Hepburn, AL, Narat, S, Mason, JC, The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology (Oxford) 49 (2010), 2243–2254 doi:10.1093/rheumatology/keq269.
28. 28 Dorsch, CA, Meyerhoff, J, Mechanisms of abnormal platelet aggregation in systemic lupus erythematosus. Arthritis Rheum 25 (1982), 966–973.
29. 29 Fuse, I, Hattori, A, Higashihara, M, Takizawa, S, Takeshige, T, Hanano, M, et al. A defect of platelet release reaction in a patient with SLE: impaired platelet aggregation induced by phorbol ester with a normal phosphorylation of 40K protein. Scand J Haematol 36 (1986), 44–54.
30. 30 Cheng, H-H, Ho, C-M, Huang, C-J, Hsu, S-S, Jiann, B-P, Chen, J-S, et al. Defect in regulation of Ca2+ movement in platelets from patients with systemic lupus erythematosus. Pharmacology 73 (2005), 169–174 doi:10.1159/000082610.
31. 31 Malpass, TW, Savage, B, Hanson, SR, Slichter, SJ, Harker, LA, Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders. J Lab Clin Med 103 (1984), 894–904.
32. 32 Ushikubi, F, Okuma, M, Kanaji, K, Sugiyama, T, Ogorochi, T, Narumiya, S, et al. Hemorrhagic thrombocytopathy with platelet thromboxane A2 receptor abnormality: defective signal transduction with normal binding activity. Thromb Haemost 57 (1987), 158–164.
33. 33 Schafer, AI, Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. N Engl J Med 306 (1982), 381–386 doi:10.1056/NEJM198202183060701.
34. 34 Kaywin, P, McDonough, M, Insel, PA, Shattil, SJ, Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors. N Engl J Med 299 (1978), 505–509 doi:10.1056/NEJM197809072991002.
35. 35 Lamrani, L, Lacout, C, Ollivier, V, Denis, CV, Gardiner, E, Ho-Tin-Noé, B, et al. Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. Blood 124 (2014), 1136–1145 doi:10.1182/blood-2013-10-530832.
36. 36 Berndt, MC, Kabral, A, Grimsley, P, Watson, N, Robertson, TI, Bradstock, KF, An acquired Bernard-Soulier-like platelet defect associated with juvenile myelodysplastic syndrome. Br J Haematol 68 (1988), 97–101.
37. 37 Budde, U, Scharf, RE, Franke, P, Hartmann-Budde, K, Dent, J, Ruggeri, ZM, Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 82 (1993), 1749–1757.
38. 38 Holme, S, Murphy, S, Platelet abnormalities in myeloproliferative disorders. Clin Lab Med 10 (1990), 873–888.
39. 39 Michiels, JJ, Berneman, Z, Schroyens, W, Finazzi, G, Budde, U, van Vliet, HHDM, The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 32 (2006), 589–604 doi:10.1055/s-2006-949664.
40. 40 Bryckaert, M, Rosa, J-P, Denis, CV, Lenting, PJ, Of von Willebrand factor and platelets. Cellular and Molecular Life Sciences (CMLS) 72 (2015), 307–326 doi:10.1007/s00018-014-1743-8.
41. 41 Rayes, J, Hollestelle, MJ, Legendre, P, Marx, I, De Groot, PG, Christophe, OD, et al. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. Blood 115 (2010), 4870–4877 doi:10.1182/blood-2009-11-254193.
42. 42 Nurden, P, Debili, N, Vainchenker, W, Bobe, R, Bredoux, R, Corvazier, E, et al. Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe thrombocytopenia. Blood 108 (2006), 2587–2595 doi:10.1182/blood-2006-03-009449.
43. 43 Nurden, P, Chretien, F, Poujol, C, Winckler, J, Borel-Derlon, A, Nurden, A, Platelet ultrastructural abnormalities in three patients with type 2B von Willebrand disease. Br J Haematol 110 (2000), 704–714.
44. 44 Casari, C, Du, V, Wu, Y-P, Kauskot, A, De Groot, PG, Christophe, OD, et al. Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia. Blood 122 (2013), 2893–2902 doi:10.1182/blood-2013-03-493312.
45. 45 López-Fernández, MF, López-Berges, C, Martín-Bernal, JA, Sánchez, R, Villarón, LG, Díez-Jarilla, J, et al. Type IIB von Willebrand's disease associated with a complex thrombocytopenic thrombocytopathy. Am J Hematol 27 (1988), 291–298.
46. 46 Sugimoto, M, Matsui, H, Mizuno, T, Tsuji, S, Miyata, S, Matsumoto, M, et al. Mural thrombus generation in type 2A and 2B von Willebrand disease under flow conditions. Blood 101 (2003), 915–920 doi:10.1182/blood-2002-03-0944.
47. 47 Casari, C, Berrou, E, Lebret, M, Adam, F, Kauskot, A, Bobe, R, et al. von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3. J Clin Invest 123 (2013), 5071–5081 doi:10.1172/JCI69458.
48. 48 Stefanini, L, Bergmeier, W, RAP1-GTPase signaling and platelet function. J Mol Med, 2015 doi:10.1007/s00109-015-1346-3.
49. 49 Cifuni, SM, Wagner, DD, Bergmeier, W, CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin alphaIIbbeta3 in platelets. Blood 112 (2008), 1696–1703 doi:10.1182/blood-2008-02-139733.
50. 50 Stefanini, L, Paul, DS, Robledo, RF, Chan, ER, Getz, TM, Campbell, RA, et al. RASA3 is a critical inhibitor of RAP1-dependent platelet activation. J Clin Invest, 2015, 1419–1432 in press doi:10.1172/JCI77993.
51. 51 Guerrero, JA, Kyei, M, Russell, S, Liu, J, Gartner, TK, Storrie, B, et al. Visualizing the von Willebrand factor/glycoprotein Ib-IX axis with a platelet-type von Willebrand disease mutation. Blood 114 (2009), 5541–5546 doi:10.1182/blood-2009-03-210823.
52. 52 Federici, AB, Berkowitz, SD, Lattuada, A, Mannucci, PM, Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis. Blood 81 (1993), 720–725.
53. 53 Mannucci, PM, Desmopressin (DDAVP) for treatment of disorders of hemostasis. Prog Hemost Thromb 8 (1986), 19–45.